Stockholders Approve Expanded Equity Incentive Plan, Increasing Potential Dilution

summarizeSummary

Stockholders approved an amendment to the company's equity incentive plan, expanding the base for annual share reserve increases to include pre-funded warrants, which will lead to greater potential dilution.

check_boxKey Events

• Equity Incentive Plan Amendment Approved

  Stockholders approved the Amended and Restated 2021 Equity Incentive Plan at the Annual Meeting on June 11, 2026.

• Expanded Share Reserve Calculation

  The 'Evergreen Provision' for annual share reserve increases will now include shares issuable from pre-funded warrants in its calculation base, alongside issued and outstanding common stock. This change increases the potential for future share issuance and dilution.

• Routine Annual Meeting Approvals

  Stockholders also elected two Class II Directors (Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D.) and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026.

auto_awesomeAnalysis

Vor Biopharma's stockholders have approved an amendment to the 2021 Equity Incentive Plan. The most significant change is to the "Evergreen Provision," which automatically increases the share reserve each year. This increase will now be calculated based on the sum of both issued and outstanding common stock AND shares issuable upon the exercise of any pre-funded warrants. This expansion of the calculation base means a larger number of shares will be added to the equity award pool annually, leading to a greater potential for future dilution for existing shareholders. This approval finalizes a proposal previously disclosed in a proxy statement on April 27, 2026.